Chronic Rhinosinusitis Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) – Estimates DelveInsight | AstraZeneca, GlycoMira, Lyra Therapeutics, Pfizer, Regeneron

Chronic Rhinosinusitis Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) - Estimates DelveInsight | AstraZeneca, GlycoMira, Lyra Therapeutics, Pfizer, Regeneron
Delveinsight Business Research LLP
As per DelveInsight, the Chronic Rhinosinusitis Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Chronic Rhinosinusitis and the launch of new therapies in the market.

DelveInsight’s “Chronic Rhinosinusitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Rhinosinusitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Chronic Rhinosinusitis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Rhinosinusitis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Chronic Rhinosinusitis: An Overview

Chronic Rhinosinusitis (CRS) is an inflammatory condition of the paranasal sinuses that most often causes chronic sinonasal symptoms. It is a disease of inflammation of the nose and paranasal sinuses and upper airways characterized by 12 weeks of persistent symptoms, including congestion, stuffiness, nasal discharge, pain or facial pressure, impairment or loss of the sense of smell (anosmia), cough, and fatigue.

Chronic Rhinosinusitis (CRS) can be classified according to the presence of a nasal polyp (NP): CRS with NP (CRSwNP) and CRS without NP (CRSsNP). CRSwNP has characteristics with high infiltration of tissue eosinophilia with a burst of Th2 inflammatory cytokine. CRSwNP can be further classified into eosinophilic and noneosinophilic. According to a study by Elisabeth et al., CRS is approximately twice as common in females as compared to males.

Chronic Rhinosinusitis Market Key Facts

  • The study by Sedaghat et al., titled “Chronic Rhinosinusitis”, estimates that chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses with a prevalence of 1–5% in the United States.

  • According to the Royal College of Surgeons, Chronic Rhinosinusitis is a highly prevalent condition affecting 10% of the UK adult population.

  • According to Stevens et al., CRSwNP is estimated to occur in seven percent of all asthmatics while asthma is reported in 26–48% of patients with CRSwNP. Furthermore, CRSwNP is a disease of middle age, with the average age of onset being 42 years and the typical age of diagnosis ranging from 40 years to 60 years.

Chronic Rhinosinusitis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Rhinosinusitis pipeline therapies. It also thoroughly assesses the Chronic Rhinosinusitis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Chronic Rhinosinusitis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Chronic Rhinosinusitis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Chronic Rhinosinusitis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chronic Rhinosinusitis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Chronic Rhinosinusitis Epidemiology, Segmented as –

  • Total Prevalent Cases of Chronic Rhinosinusitis (CRS) in the 7MM (2019–2032)

  • Gender-Specific Prevalent Cases of CRS in the 7MM (2019–2032)

  • Type-Specific Prevalent Cases of CRS (CRSwNP and CRSsNP) in the 7MM (2019–2032)

  • Diagnosed and Treatable Cases of CRS in the 7MM (2019–2032)

Chronic Rhinosinusitis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chronic Rhinosinusitis market or expected to be launched during the study period. The analysis covers the Chronic Rhinosinusitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chronic Rhinosinusitis drugs based on their sale and market share.

The report also covers the Chronic Rhinosinusitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chronic Rhinosinusitis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Chronic Rhinosinusitis Market Will Evolve and Grow by 2032 @

Chronic Rhinosinusitis Therapeutics Analysis

There are no definitive guidelines for the treatment of Chronic Rhinosinusitis, largely due to the lack of consensus on the etiology of the disease. Chronic Rhinosinusitis has commonly been treated with courses of oral antibiotics, but the lack of clinical evidence for their efficacy in Chronic Rhinosinusitis makes this therapy controversial unless the patient is suffering from a superimposed acute bacterial inflammation upon the underlying chronic inflammatory condition.

Several major pharma and biotech companies are developing therapies for Chronic Rhinosinusitis. Currently, Lyra Therapeutics is leading the therapeutics market with its Chronic Rhinosinusitis drug candidates in the most advanced stage of clinical development.

On April 25, 2023, Lyra Therapeutics announced that it has resumed screening and enrollment in ENLIGHTEN II, its second pivotal Phase 3 clinical trial of LYR-210 in patients with CRS. LYR-210 is a bioresorbable nasal implant designed as an alternative to sinus surgery for the millions of CRS patients who remain symptomatic despite treatment.

Chronic Rhinosinusitis Companies Actively Working in the Therapeutics Market Include

  • AstraZeneca

  • Connect Biopharma

  • GlycoMira Therapeutics

  • Keymed Biosciences Co.Ltd

  • Kyowa Kirin Co., Ltd.

  • Lyra Therapeutics

  • Pfizer

  • Regeneron Pharmaceuticals

  • Sanotize Research and Development Corp.

And many others

Emerging and Marketed Chronic Rhinosinusitis Therapies Covered in the Report Include:

  • CBP-201: Connect Biopharma

  • Dupixent (dupilumab): Sanofi

  • Etokimab: AnaptysBio

  • GB001: Gossamer Bio

  • LYR-210: Lyra Therapeutics

  • SINUVA: Intersect

  • Xolair (omalizumab): Genentech

And many more

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Chronic Rhinosinusitis Competitive Intelligence Analysis

4. Chronic Rhinosinusitis Market Overview at a Glance

5. Chronic Rhinosinusitis Disease Background and Overview

6. Chronic Rhinosinusitis Patient Journey

7. Chronic Rhinosinusitis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Chronic Rhinosinusitis Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Rhinosinusitis Unmet Needs

10. Key Endpoints of Chronic Rhinosinusitis Treatment

11. Chronic Rhinosinusitis Marketed Therapies

12. Chronic Rhinosinusitis Emerging Drugs and Latest Therapeutic Advances

13. Chronic Rhinosinusitis Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Rhinosinusitis Market Outlook (In US, EU5, and Japan)

16. Chronic Rhinosinusitis Companies Active in the Market

17. Chronic Rhinosinusitis Access and Reimbursement Overview

18. KOL Views on the Chronic Rhinosinusitis Market

19. Chronic Rhinosinusitis Market Drivers

20. Chronic Rhinosinusitis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Kyphoscoliosis Market

“Kyphoscoliosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Kyphoscoliosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Kyphoscoliosis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States